Literature DB >> 36181610

Cardio-Oncology in Childhood: State of the Art.

Elena Bennati1, Francesca Girolami2, Gaia Spaziani2, Giovanni Battista Calabri2, Claudio Favre3, Iris Parrini4, Fabiana Lucà5, Angela Tamburini3, Silvia Favilli2.   

Abstract

PURPOSE OF REVIEW: Cardio-oncology is an increasingly important field of cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease (CVD) occurring during and after oncological treatments. The survival rate for childhood cancer patients has dramatically increased thanks to new treatment protocols and cardiovascular (CV) sequelae represent the third most frequent cause of mortality in surviving patients. This study aims to provide a complete and updated review of all the main aspects of cardio-oncology in childhood and to highlight the critical issues. RECENT
FINDINGS: The problem of CV complications in childhood cancer survivors raises the need to make an early diagnosis of cardiotoxicity by the new imaging and laboratory techniques in order to intervene promptly and to implement pharmacological strategies and lifestyle changes to reduce or even to prevent cardiac injury. Furthermore, a stratification of CV risk, also including new predisposing factors such as the presence of some genetic mutations, is of paramount importance before undertaking oncological treatments. Besides, a systematic and personalized planning of long-term follow-up is fundamental to ensure a transition from pediatric to adult hospital and to avoid missed or late diagnosis of cardiomyopathy. We reviewed the main risk factors for cardiotoxicity in children, both traditional and emerging ones: the mechanisms of toxicity of both old and new antineoplastic therapies, the techniques for detecting cardiac damage, and the current evidence regarding pharmacological cardioprotection. At the end, we focused our attention on the existing guidelines and strategies about the long-term follow-up of childhood cancer survivors.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anthracycline; Cardio-oncology; Cardiotoxicity; Childhood cancer survivors; Pediatric cancer

Year:  2022        PMID: 36181610     DOI: 10.1007/s11912-022-01329-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  75 in total

1.  Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?

Authors:  Maarten P van den Berg; Karin Y van Spaendonck-Zwarts; Dirk J van Veldhuisen; Jourik A Gietema; Aleida Postma; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2010-10-16       Impact factor: 15.534

Review 2.  Second Hits in Dilated Cardiomyopathy.

Authors:  Peter Marstrand; Kermshlise Picard; Neal K Lakdawala
Journal:  Curr Cardiol Rep       Date:  2020-01-24       Impact factor: 2.931

3.  Anthracycline-induced cardiomyopathy in siblings with early breast cancer.

Authors:  A C Young; B Mercer; T J Perren; D Dodwell
Journal:  Ann Oncol       Date:  2011-05-09       Impact factor: 32.976

Review 4.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

5.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Authors:  J P Krischer; S Epstein; D D Cuthbertson; A M Goorin; M L Epstein; S E Lipshultz
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

Review 6.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.

Authors:  Joseph R Carver; Charles L Shapiro; Andrea Ng; Linda Jacobs; Cindy Schwartz; Katherine S Virgo; Karen L Hagerty; Mark R Somerfield; David J Vaughn
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

Review 7.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

Review 8.  Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.

Authors:  Vivian Y Chang; Jessica J Wang
Journal:  Curr Oncol Rep       Date:  2018-04-30       Impact factor: 5.075

Review 9.  Pediatric Chemotherapy Drugs Associated With Cardiotoxicity.

Authors:  Gazala Hitawala; Esha Jain; Lisett Castellanos; Radhika Garimella; Radhika Akku; Adila K Chamavaliyathil; Huma Irfan; Vikash Jaiswal; Jonathan Quinonez; Maher Dakroub; Muhammad Hanif; Ali H Baloch; Ivan S Gomez; John Dylewski
Journal:  Cureus       Date:  2021-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.